ENDONOVO THERAPEUTICS, INC. (ENDV) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29272H3003

Price
0.00 USD
Market cap
180,755.63 USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
7.54 %
Return on assets (ROA)
-11,275.28 %

ENDONOVO THERAPEUTICS, INC. financials

Fiscal year20242025
Revenue10,043.00 USD–
Gross profit-615,198.00 USD–
Operating income-1.56 m USD-945,766.00 USD
Net income-2.80 m USD-2.18 m USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ENDONOVO THERAPEUTICS, INC.

Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.